AU8742198A - Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity - Google Patents

Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity

Info

Publication number
AU8742198A
AU8742198A AU87421/98A AU8742198A AU8742198A AU 8742198 A AU8742198 A AU 8742198A AU 87421/98 A AU87421/98 A AU 87421/98A AU 8742198 A AU8742198 A AU 8742198A AU 8742198 A AU8742198 A AU 8742198A
Authority
AU
Australia
Prior art keywords
enzyme activity
diseases associated
treating diseases
cholinesterase inhibitor
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU87421/98A
Inventor
James Robert Murray
Ernir Snorrason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire International Licensing BV
Original Assignee
Shire International Licensing BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9717401.5A external-priority patent/GB9717401D0/en
Priority claimed from GBGB9717399.1A external-priority patent/GB9717399D0/en
Application filed by Shire International Licensing BV filed Critical Shire International Licensing BV
Publication of AU8742198A publication Critical patent/AU8742198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
AU87421/98A 1997-08-15 1998-08-14 Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity Abandoned AU8742198A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9717401.5A GB9717401D0 (en) 1997-08-15 1997-08-15 Treatment of psoriasis
GBGB9717399.1A GB9717399D0 (en) 1997-08-15 1997-08-15 Method of treatment
GB9717401 1997-08-15
GB9717399 1997-08-15
PCT/GB1998/002448 WO1999008672A1 (en) 1997-08-15 1998-08-14 Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity

Publications (1)

Publication Number Publication Date
AU8742198A true AU8742198A (en) 1999-03-08

Family

ID=26312077

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87421/98A Abandoned AU8742198A (en) 1997-08-15 1998-08-14 Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity

Country Status (2)

Country Link
AU (1) AU8742198A (en)
WO (1) WO1999008672A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304904B1 (en) * 1998-09-11 2001-04-05 Eisai Co Ltd ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME
DE19845372A1 (en) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Use of catechol derivatives as proteinase inhibitors
IL158600A (en) 2003-10-26 2015-07-30 Hermona Soreq Acetylcholinesterase antisense deoxyoligonucleotide as an anti-inflammatory agent
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
GB2419093A (en) * 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
EP1807087A2 (en) * 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
ES2881081T3 (en) 2013-03-15 2021-11-26 Agenebio Inc Procedures and compositions to improve cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2023070351A1 (en) * 2021-10-27 2023-05-04 香港理工大学 Prevention and treatment of osteoarticular diseases by inhibiting acetylcholinesterase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491679A (en) * 1975-01-09 1977-11-09 Gallardo Antonio Sa Pharmaceutical compositions
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
GB9606736D0 (en) * 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine

Also Published As

Publication number Publication date
WO1999008672A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
GB9624258D0 (en) Inhibitors of rotamase enzyme activity
LT98002A (en) Inhibitors of rotamase enzyme activity
PL326420A1 (en) Inhibitors of rotamase enzymatic activity
AU3697995A (en) An enzyme with lipolytic activity
LT98001A (en) Small molecule inhibitors of rotamase enzyme activity
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AU3758695A (en) Oxidoreductase activity of manganic porphyrins
AU5597098A (en) Inhibitors of the enzymatic activity of psa
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
GB9616282D0 (en) Enzyme activity enhancement
EP0994707A4 (en) Inhibitors of naaladase enzyme activity
AU1390199A (en) Compositions and methods for inhibiting the activity of certain genes
AU8479498A (en) Dual specificity phosphatase and methods of use
AU1092297A (en) Selective inactivation of enzyme activities
AU9257998A (en) Method for enhancing the activity of an enzyme
AUPP697698A0 (en) Regulation of enzyme activity
AU5530800A (en) Method and composition for enhancing the activity of an enzyme
AU9797598A (en) Treatment of diabetic retinopathy
GB9216582D0 (en) Determination of enzyme activity
AU1143601A (en) Method and composition for enhancing the activity of an enzyme
AU9254498A (en) Preparation of enzyme with reduced beta-lactamase activity
AU8064998A (en) Fibronectin antagonists as therapeutic agents and broad-spectrum enha ncers of antibiotic therapy
AU1068500A (en) Quantitative measurement of enzyme activity
AU6962798A (en) Assay for determination of neuronal activity in brain tissue

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase